Camurus AB operates as a research based pharmaceutical company. The company is headquartered in Lund, Skane and currently employs 285 full-time employees. The company went IPO on 2015-12-03. The firm has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
根据最新的财务报表(Form-10K),Camurus AB (publ) 的总资产为 $4,739,净利润为 $735
CAMRF 的关键财务比率是什么?
Camurus AB (publ) 的流动比率是 9.4,净利 margin 为 32.45,每股销售为 $38.23。
Camurus AB (publ) 的收入按细分市场或地理位置如何划分?
Camurus AB (publ) 最大收入来源是 Sales of Development Related Goods and Services,在最近的收益报告中收入为 2,252,000。就地区而言, Sweden 是 Camurus AB (publ) 的主要市场,收入为 117,170,000。